Efficacy and Safety of Anti-Trop-2 Antibody Drug Conjugate Sacituzumab Govitecan (IMMU-132) in Heavily Pretreated Patients With Metastatic Triple-Negative Breast Cancer
Aditya Bardia(UCLA Health), Linda T. Vahdat(Dartmouth–Hitchcock Medical Center), Michael J. Guarino(Dana-Farber Cancer Institute), William A. Wegener(Children's Hospital of Philadelphia), Jordan Berlin(Dana-Farber Cancer Institute), Joyce O’Shaughnessy(Baylor University Medical Center), Robert M. Sharkey(Immunomedics (United States)), Serengulam V. Govindan(Dana-Farber Cancer Institute), Jennifer R. Diamond(University of Colorado Anschutz Medical Campus), Allyson J. Ocean(Dana-Farber Cancer Institute), Kevin Kalinsky(Emory University), Sara M. Tolaney(Harvard University), Ingrid A. Mayer(Vanderbilt University), Pius Maliakal(Dana-Farber Cancer Institute), Vandana G. Abramson(Vanderbilt University), Wells A. Messersmith(University of Colorado Cancer Center), Dejan Juric(Massachusetts General Hospital), Nikita Shah(Orlando Health), Alexander Starodub(Dana-Farber Cancer Institute), Steven J. Isakoff(Harvard University), Rebecca Moroose(Orlando Health), David M. Goldenberg(Unknown)
Cited by 407
Related Papers
Phase 3 Trial of <sup>177</sup> Lu-Dotatate for Midgut Neuroendocrine Tumors
|New England Journal of Medicine|2017|3.2k
Pembrolizumab for Early Triple-Negative Breast Cancer
|New England Journal of Medicine|2020|3.1k
Circulating Tumor Cell Clusters Are Oligoclonal Precursors of Breast Cancer Metastasis
|Cell|2014|2.5k